Nutriband Files Patent to Protect AVERSA Abuse-Deterrent Tech

Nutriband (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office to bolster intellectual property protection for its AVERSA™ abuse-deterrent transdermal technology. The application covers improved aversive formulations and coating methods designed to enhance the technology's abuse-deterrent properties. If granted, the patent could extend protection for AVERSA™-based products, including AVERSA™ FENTANYL, through 2046. Nutriband currently holds patents in 46 countries covering its technology, which incorporates aversive agents into transdermal patches to help prevent abuse, diversion, misuse, and accidental exposure involving drugs with abuse potential, including opioids and stimulants.

The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA™ technology, which can be integrated into any transdermal patch to deter the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This patent filing represents a significant step in strengthening Nutriband’s intellectual property portfolio and potentially extending market exclusivity for its innovative products. For more details, view the full press release at https://ibn.fm/Osmxh.

The announcement was disseminated through MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance visibility of private and public companies. MissionIR is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. Nutriband’s latest news and updates are available in its newsroom at https://ibn.fm/NTRB.